InterVenn Biosciences Reports Results on Vista™ : a Multi-Indication Liquid Biopsy Research Panel Built on Glycoproteomics
Summary
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--InterVenn Biosciences today announced that its proprietary liquid biopsy glycoproteomic research panel, Vista™, has demonstrated multi-indication performance in early cancer detection based on tests run in the company’s Bay Area laboratory. InterVenn, in collaboration with several large pharma-biotech and diagnostic users of Vista™, has been able to repeatedly and reliably generate multivariable glycopeptide classifiers for a range of different forms of cancer with sensitivities and specificities consistently above 90 and as high as 98 percent. InterVenn and its research partners have used Vista™ to demonstrate the power of glycoproteomic profiles as biomarkers for over a dozen different oncology indications, including ovarian, renal, lung, liver, prostate, pancreas, nasopharyngeal, and colorectal cancer, as well as to predict the response to checkpoint-inhibitor treatment. Vista™’s application-specific disease classifier panels each consist of a limited number of glycopeptide signatures provide highly targeted readouts with accuracy rates that the “one-size-fits-all approaches” pursued by others have so far generally failed to achieve. Rather than utilizing sequencing technologies, InterVenn has focused its exploratory work on characterizing glycoprotein profiles, arguing that the considerably higher complexity and dynamic range of proteins and their post-translational modifications provide the deep repertoire of analytes that is likely required to yield the resolution needed for highly accurate biomarker panels.